Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate governance notification and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported. The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs).
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: October 25, 2013 (Notification date: October 28, 2013).
- Instrument: GSK American Depositary Shares (ADSs).
- Price: $52.05 per ADS.
- Parties Involved: Dr. M. Slaoui (Director) and Dr. K. Slaoui (Connected Person).
- Allocation Details: Dr. M. Slaoui received no additional ADSs; Dr. K. Slaoui received an increase of 4 ADSs.
- Context: The change resulted from a revaluation of the cash element within the GSK 401K plan.